Leading Urologists Present Studies at the American Urological Association Supporting Use of the Matritech, Inc.'s NMP22(R) BladderChek(R) Test for Diagnosing and Managing Bladder Cancer

Published: May 23, 2007

NEWTON, Mass.--(BUSINESS WIRE)--Matritech’s (Amex: MZT) NMP22® BladderChek® Test was recognized by leading clinical investigators at the 2007 annual meeting of the American Urological Association (AUA) for use in diagnosing and managing bladder cancer. New information showing the reliability of the test as a diagnostic tool in evaluating patients with risk factors for bladder cancer was also presented. People at risk for bladder cancer include long-time smokers, workers in manufacturing areas where particulate matter is concentrated, workers who encounter chemical vapors including hair dyes, and fire fighters who are exposed to toxic fumes.

Back to news